Symbols / XBIT $2.25 -2.17%
XBIT Chart
About
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 68.60M |
| Enterprise Value | -55.43M | Income | -45.54M | Sales | — |
| Book/sh | 4.60 | Cash/sh | 4.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | 17.31 | PEG | — |
| P/S | — | P/B | 0.49 | P/C | — |
| EV/EBITDA | 1.03 | EV/Sales | — | Quick Ratio | 15.88 |
| Current Ratio | 16.01 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.95 | EPS next Y | 0.13 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2020-05-11 17:00 | ROA | -19.93% |
| ROE | -28.23% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 30.49M |
| Shs Float | 19.09M | Short Float | 0.56% | Short Ratio | 2.97 |
| Short Interest | — | 52W High | 3.62 | 52W Low | 2.09 |
| Beta | 0.89 | Avg Volume | 38.87K | Volume | 66.26K |
| Target Price | — | Recom | None | Prev Close | $2.30 |
| Price | $2.25 | Change | -2.17% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.25
Latest analyst target
3. DCF / Fair value
$-15.51
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.25
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2020-04-07 | main | Piper Sandler | — → Overweight | $18 |
| 2019-12-11 | main | Piper Sandler | — → Overweight | $28 |
| 2019-06-14 | init | Piper Sandler | — → Overweight | $13 |
- XBiotech (NASDAQ:XBIT) Stock Price Passes Below Two Hundred Day Moving Average - What's Next? - MarketBeat Sat, 14 Mar 2026 08
- XBiotech: Q4 Earnings Snapshot - KING5.com Fri, 13 Mar 2026 20
- XBiotech: Q4 Earnings Snapshot - marketscreener.com Fri, 13 Mar 2026 20
- Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation - Yahoo Finance Fri, 16 May 2025 07
- 3 Promising Penny Stocks With Market Caps Over $30M - simplywall.st Fri, 19 Dec 2025 08
- XBiotech Inc.'s (NASDAQ:XBIT) largest shareholders are individual investors with 49% ownership, insiders own 35% - Yahoo Finance Fri, 10 Jan 2025 08
- XBIT Stock Price and Chart — NASDAQ:XBIT - TradingView Fri, 21 Jul 2017 05
- XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders - Yahoo Finance hu, 28 Aug 2025 07
- Top XBiotech (XBIT) Competitors 2026 - MarketBeat hu, 30 Apr 2020 16
- XBIT price today, XBT to USD live price, marketcap and chart - CoinMarketCap ue, 20 Oct 2020 21
- XBiotech Inc. announced that it expects to receive $10 million in funding - marketscreener.com ue, 02 Jan 2024 08
- XBiotech (XBIT) Stock Forecast & Price Prediction 2026–2030 - CoinCodex Wed, 24 Mar 2021 01
- Xbit (XBT) Price Prediction 2026, 2027-2030 - CoinCodex Fri, 07 Jan 2022 20
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -5.53K | 397.53K | -56.00K | -224.68K |
| TaxRateForCalcs | 0.00 | 0.21 | 0.02 | 0.32 |
| NormalizedEBITDA | -30.48M | -24.46M | -29.08M | -21.72M |
| TotalUnusualItems | -5.53M | 1.89M | -2.80M | -711.00K |
| TotalUnusualItemsExcludingGoodwill | -5.53M | 1.89M | -2.80M | -711.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -38.53M | -24.56M | -32.90M | -17.41M |
| ReconciledDepreciation | 1.75M | 1.74M | 2.61M | 2.65M |
| ReconciledCostOfRevenue | 0.00 | 651.00K | 5.82M | |
| EBITDA | -36.01M | -22.57M | -31.88M | -22.43M |
| EBIT | -37.76M | -24.31M | -34.49M | -25.08M |
| NetInterestIncome | 9.01M | 10.42M | 3.82M | 467.00K |
| InterestExpense | 807.00K | 0.00 | ||
| InterestIncome | 9.81M | 10.42M | 3.82M | 467.00K |
| NormalizedIncome | -33.01M | -26.05M | -30.16M | -16.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -38.53M | -24.56M | -32.90M | -17.41M |
| TotalExpenses | 42.47M | 37.51M | 38.50M | 43.48M |
| TotalOperatingIncomeAsReported | -42.47M | -37.51M | -34.49M | -25.08M |
| DilutedAverageShares | 30.46M | 30.44M | 30.44M | 30.04M |
| BasicAverageShares | 30.46M | 30.44M | 30.44M | 30.04M |
| DilutedEPS | -1.26 | -0.81 | -1.08 | -0.58 |
| BasicEPS | -1.26 | -0.81 | -1.08 | -0.58 |
| DilutedNIAvailtoComStockholders | -38.53M | -24.56M | -32.90M | -17.41M |
| NetIncomeCommonStockholders | -38.53M | -24.56M | -32.90M | -17.41M |
| NetIncome | -38.53M | -24.56M | -32.90M | -17.41M |
| NetIncomeIncludingNoncontrollingInterests | -38.53M | -24.56M | -32.90M | -17.41M |
| NetIncomeContinuousOperations | -38.53M | -24.56M | -32.90M | -17.41M |
| TaxProvision | -32.00K | 244.00K | -688.00K | -8.04M |
| PretaxIncome | -38.56M | -24.31M | -33.59M | -25.46M |
| OtherIncomeExpense | -5.10M | 2.78M | -2.92M | -843.00K |
| OtherNonOperatingIncomeExpenses | 432.00K | 883.00K | -121.00K | -132.00K |
| SpecialIncomeCharges | 0.00 | |||
| GainOnSaleOfPPE | 0.00 | |||
| GainOnSaleOfSecurity | -5.53M | 1.89M | -2.80M | -711.00K |
| NetNonOperatingInterestIncomeExpense | 9.01M | 10.42M | 3.82M | 467.00K |
| InterestExpenseNonOperating | 807.00K | 0.00 | ||
| InterestIncomeNonOperating | 9.81M | 10.42M | 3.82M | 467.00K |
| OperatingIncome | -42.47M | -37.51M | -34.49M | -25.08M |
| OperatingExpense | 42.47M | 37.51M | 37.85M | 37.66M |
| ResearchAndDevelopment | 37.76M | 32.85M | 31.54M | 28.27M |
| SellingGeneralAndAdministration | 4.71M | 4.66M | 6.30M | 9.39M |
| GeneralAndAdministrativeExpense | 4.71M | 4.66M | 6.30M | 9.39M |
| OtherGandA | 2.56M | 2.92M | 2.39M | 3.25M |
| SalariesAndWages | 2.15M | 1.75M | 3.92M | 6.13M |
| GrossProfit | 0.00 | 3.36M | 12.57M | |
| CostOfRevenue | 0.00 | 651.00K | 5.82M | |
| TotalRevenue | 0.00 | 0.00 | 4.01M | 18.39M |
| OperatingRevenue | 0.00 | 0.00 | 4.01M | 18.39M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 30.49M | 30.44M | 30.44M | 30.44M |
| ShareIssued | 30.49M | 30.44M | 30.44M | 30.44M |
| TotalDebt | 10.25M | |||
| TangibleBookValue | 182.27M | 218.85M | 240.40M | 269.38M |
| InvestedCapital | 192.52M | 218.85M | 240.40M | 269.38M |
| WorkingCapital | 159.46M | 195.62M | 215.78M | 243.42M |
| NetTangibleAssets | 182.27M | 218.85M | 240.40M | 269.38M |
| CommonStockEquity | 182.27M | 218.85M | 240.40M | 269.38M |
| TotalCapitalization | 182.27M | 218.85M | 240.40M | 269.38M |
| TotalEquityGrossMinorityInterest | 182.27M | 218.85M | 240.40M | 269.38M |
| StockholdersEquity | 182.27M | 218.85M | 240.40M | 269.38M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 826.00K | 1.97M | |
| OtherEquityAdjustments | 826.00K | 1.97M | ||
| RetainedEarnings | -90.84M | -52.31M | -27.75M | 5.15M |
| CapitalStock | 273.11M | 271.15M | 267.32M | 262.26M |
| CommonStock | 273.11M | 271.15M | 267.32M | 262.26M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 16.82M | 7.77M | 5.70M | 5.79M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.72M | 1.67M | 1.64M | 2.34M |
| TradeandOtherPayablesNonCurrent | 1.72M | 1.67M | 1.58M | 1.47M |
| NonCurrentDeferredLiabilities | 0.00 | 59.00K | 873.00K | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 59.00K | 873.00K | |
| CurrentLiabilities | 15.11M | 6.10M | 4.07M | 3.45M |
| CurrentDebtAndCapitalLeaseObligation | 10.25M | |||
| CurrentDebt | 10.25M | |||
| OtherCurrentBorrowings | 10.25M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 611.00K | 562.00K | 489.00K | 480.00K |
| PayablesAndAccruedExpenses | 4.24M | 5.54M | 3.58M | 2.97M |
| CurrentAccruedExpenses | 2.02M | 2.94M | 1.11M | 894.00K |
| InterestPayable | 404.00K | 0.00 | ||
| Payables | 2.22M | 2.60M | 2.46M | 2.08M |
| TotalTaxPayable | 0.00 | 83.00K | 55.00K | 10.00K |
| IncomeTaxPayable | 0.00 | 83.00K | 55.00K | 10.00K |
| AccountsPayable | 2.22M | 2.52M | 2.41M | 2.07M |
| TotalAssets | 199.09M | 226.62M | 246.10M | 275.18M |
| TotalNonCurrentAssets | 24.53M | 24.90M | 26.26M | 28.31M |
| NonCurrentDeferredAssets | 0.00 | |||
| NonCurrentDeferredTaxesAssets | 0.00 | |||
| NetPPE | 24.53M | 24.90M | 26.26M | 28.31M |
| AccumulatedDepreciation | -19.98M | -18.24M | -16.50M | -15.73M |
| GrossPPE | 44.51M | 43.14M | 42.76M | 44.04M |
| ConstructionInProgress | 1.71M | 469.00K | 401.00K | 2.06M |
| OtherProperties | 16.49M | 16.37M | 16.06M | 16.83M |
| MachineryFurnitureEquipment | 724.00K | 709.00K | 704.00K | 958.00K |
| BuildingsAndImprovements | 24.17M | 24.17M | 24.17M | 22.77M |
| LandAndImprovements | 1.42M | 1.42M | 1.42M | 1.42M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 174.57M | 201.72M | 219.84M | 246.87M |
| OtherCurrentAssets | 1.03M | 760.00K | 601.00K | 934.00K |
| CurrentDeferredAssets | 0.00 | |||
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 934.00K | |||
| Receivables | 858.00K | 935.00K | 1.76M | 8.95M |
| TaxesReceivable | 158.00K | 75.00K | 548.00K | 8.95M |
| AccruedInterestReceivable | 700.00K | 860.00K | 1.22M | 0.00 |
| AccountsReceivable | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 172.68M | 200.02M | 217.48M | 236.98M |
| OtherShortTermInvestments | 0.00 | 60.17M | 0.00 | |
| CashAndCashEquivalents | 172.68M | 200.02M | 157.31M | 236.98M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -32.27M | -19.09M | -15.41M | 65.92M |
| IssuanceOfDebt | 10.25M | 0.00 | ||
| IssuanceOfCapitalStock | 0.00 | |||
| CapitalExpenditure | -1.30M | -362.00K | -585.00K | -3.52M |
| InterestPaidSupplementalData | 400.00K | 0.00 | ||
| IncomeTaxPaidSupplementalData | 85.00K | 141.00K | 0.00 | |
| EndCashPosition | 172.68M | 200.02M | 157.31M | 236.98M |
| BeginningCashPosition | 200.02M | 157.31M | 236.98M | 237.37M |
| EffectOfExchangeRateChanges | -5.53M | -46.00K | -961.00K | 705.00K |
| ChangesInCash | -21.82M | 42.76M | -78.72M | -1.09M |
| FinancingCashFlow | 10.45M | -9.00K | 0.00 | -67.01M |
| CashFlowFromContinuingFinancingActivities | 10.45M | -9.00K | 0.00 | -67.01M |
| NetOtherFinancingCharges | -14.00K | |||
| ProceedsFromStockOptionExercised | 200.00K | 5.00K | 0.00 | 8.00M |
| CashDividendsPaid | 0.00 | -75.00M | ||
| CommonStockDividendPaid | 0.00 | -75.00M | ||
| NetCommonStockIssuance | 0.00 | |||
| CommonStockIssuance | 0.00 | |||
| NetIssuancePaymentsOfDebt | 10.25M | 0.00 | ||
| NetShortTermDebtIssuance | 10.25M | 0.00 | ||
| ShortTermDebtIssuance | 10.25M | 0.00 | ||
| InvestingCashFlow | -1.30M | 61.50M | -63.89M | -3.52M |
| CashFlowFromContinuingInvestingActivities | -1.30M | 61.50M | -63.89M | -3.52M |
| NetInvestmentPurchaseAndSale | 0.00 | 61.86M | -63.31M | 0.00 |
| SaleOfInvestment | 0.00 | 61.86M | ||
| PurchaseOfInvestment | -63.31M | 0.00 | ||
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -1.30M | -362.00K | -585.00K | -3.52M |
| PurchaseOfPPE | -1.30M | -362.00K | -585.00K | -3.52M |
| OperatingCashFlow | -30.96M | -18.73M | -14.82M | 69.44M |
| CashFlowFromContinuingOperatingActivities | -30.96M | -18.73M | -14.82M | 69.44M |
| ChangeInWorkingCapital | -1.46M | 2.72M | 7.60M | 79.75M |
| ChangeInOtherWorkingCapital | -59.00K | -815.00K | 78.65M | |
| ChangeInPayablesAndAccruedExpense | -1.26M | 2.11M | 741.00K | -279.00K |
| ChangeInAccruedExpense | -877.00K | 1.90M | 229.00K | 23.00K |
| ChangeInPayable | -388.00K | 214.00K | 512.00K | -302.00K |
| ChangeInAccountPayable | -364.00K | 91.00K | 357.00K | -514.00K |
| ChangeInTaxPayable | -24.00K | 123.00K | 155.00K | 212.00K |
| ChangeInIncomeTaxPayable | -24.00K | 123.00K | 155.00K | 212.00K |
| ChangeInPrepaidAssets | -271.00K | -160.00K | 334.00K | -352.00K |
| ChangeInReceivables | 77.00K | 829.00K | 7.34M | 1.73M |
| ChangesInAccountReceivables | 0.00 | 4.11M | ||
| StockBasedCompensation | 1.75M | 3.26M | 5.06M | 4.46M |
| DepreciationAmortizationDepletion | 1.75M | 1.74M | 2.61M | 2.65M |
| DepreciationAndAmortization | 1.75M | 1.74M | 2.61M | 2.65M |
| Depreciation | 1.75M | 1.74M | 2.61M | 2.65M |
| OperatingGainsLosses | 5.53M | -1.89M | 2.80M | |
| NetForeignCurrencyExchangeGainLoss | 5.53M | -1.89M | 2.80M | 0.00 |
| GainLossOnSaleOfBusiness | 0.00 | |||
| NetIncomeFromContinuingOperations | -38.53M | -24.56M | -32.90M | -17.41M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XBIT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|